Home LiteratureArticle Details
PMID: 17069663 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Classification of ductal carcinoma in situ by gene expression profiling.

Breast cancer research : BCR ·Vol. 8 ·No. 5 ·2006-00-00 ·Pages R61

Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ

Abstract

Ductal carcinoma in situ (DCIS) is characterised by the intraductal proliferation of malignant epithelial cells. Several histological classification systems have been developed, but assessing the histological type/grade of DCIS lesions is still challenging, making treatment decisions based on these features difficult. To obtain insight in the molecular basis of the development of different types of DCIS and its progression to invasive breast cancer, we have studied differences in gene expression between different types of DCIS and between DCIS and invasive breast carcinomas. Gene expression profiling using microarray analysis has been performed on 40 in situ and 40 invasive breast cancer cases. DCIS cases were classified as well- (n = 6), intermediately (n = 18), and poorly (n = 14) differentiated type. Of the 40 invasive breast cancer samples, five samples were grade I, 11 samples were grade II, and 24 samples were grade III. Using two-dimensional hierarchical clustering, the basal-like type, ERB-B2 type, and the luminal-type tumours originally described for invasive breast cancer could also be identified in DCIS. Using supervised classification, we identified a gene expression classifier of 35 genes, which differed between DCIS and invasive breast cancer; a classifier of 43 genes could be identified separating between well- and poorly differentiated DCIS samples.

MeSH Terms
Breast Neoplasms/classification,genetics,pathology Carcinoma, Ductal, Breast/classification,genetics,pathology Carcinoma, Intraductal, Noninfiltrating/classification,genetics,pathology Female Gene Expression Profiling Humans
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Hannemann Juliane
Division of Experimental Therapy, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Velds Arno
Halfwerk Johannes B G
Kreike Bas
Peterse Johannes L
van de Vijver Marc J
References (39)
39 references, click to expand
  1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
  2. Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type.
    Br J Cancer. 1999 Dec;81(8):1410-8 PMID: 10604741
  3. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  4. Molecular characterization of the tumor microenvironment in breast cancer.
    Cancer Cell. 2004 Jul;6(1):17-32 PMID: 15261139
  5. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.
    Nat Med. 2001 Jun;7(6):673-9 PMID: 11385503
  6. Bcl2 expression and its correlation with neuroendocrine differentiation in colon carcinomas.
    Tumori. 2004 Mar-Apr;90(2):233-8 PMID: 15237588
  7. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Cancer Res. 2006 May 15;66(10):5278-86 PMID: 16707453
  8. Method for grading breast cancer.
    J Clin Pathol. 1993 Feb;46(2):189-90 PMID: 8459046
  9. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways.
    J Pathol. 1999 Mar;187(4):396-402 PMID: 10398097
  10. Classification of ductal carcinoma in situ by gene expression profiling.
    Breast Cancer Res. 2006;8(5):R61 PMID: 17069663
  11. Gene expression predictors of breast cancer outcomes.
    Lancet. 2003 May 10;361(9369):1590-6 PMID: 12747878
  12. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.
    J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 PMID: 12509396
  13. The transition from hyperplasia to invasive carcinoma of the breast.
    J Pathol. 1999 Feb;187(3):272-8 PMID: 10398078
  14. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
    Breast Cancer Res. 2003;5(5):254-7 PMID: 12927035
  15. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics.
    Oncogene. 2006 Apr 13;25(16):2328-38 PMID: 16314837
  16. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast.
    Am J Pathol. 1997 Jul;151(1):161-8 PMID: 9212742
  17. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ.
    Hum Pathol. 1999 Mar;30(3):257-62 PMID: 10088542
  18. Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
    Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 PMID: 12917485
  19. Molecular markers in ductal carcinoma in situ of the breast.
    Mol Cancer Res. 2003 Mar;1(5):362-75 PMID: 12651909
  20. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  21. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
    J Clin Oncol. 2005 May 20;23(15):3331-42 PMID: 15908647
  22. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
    Clin Exp Metastasis. 2003;20(5):459-70 PMID: 14524536
  23. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis.
    Br J Cancer. 1997;76(9):1131-3 PMID: 9365159
  24. Histological and biological evolution of human premalignant breast disease.
    Endocr Relat Cancer. 2001 Mar;8(1):47-61 PMID: 11350726
  25. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  26. The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.
    Breast Cancer Res. 2003;5(6):313-9 PMID: 14580249
  27. Analysis of gene expression in ductal carcinoma in situ of the breast.
    Clin Cancer Res. 2002 Dec;8(12):3788-95 PMID: 12473591
  28. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  29. Genesis: cluster analysis of microarray data.
    Bioinformatics. 2002 Jan;18(1):207-8 PMID: 11836235
  30. Gene expression profiles of human breast cancer progression.
    Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 PMID: 12714683
  31. Detection of ductal carcinoma in situ in women undergoing screening mammography.
    J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54 PMID: 12381707
  32. Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors.
    Pathol Oncol Res. 2002;8(1):26-30 PMID: 11994759
  33. Proteomics of human breast ductal carcinoma in situ.
    Cancer Res. 2002 Nov 15;62(22):6740-9 PMID: 12438275
  34. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  35. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
    Anticancer Res. 2003 May-Jun;23(3A):2043-51 PMID: 12894577
  36. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    J Clin Oncol. 2003 Mar 15;21(6):1022-8 PMID: 12637466
  37. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
    N Engl J Med. 1988 Nov 10;319(19):1239-45 PMID: 2903446
  38. Ductal carcinoma in situ: a proposal for a new classification.
    Semin Diagn Pathol. 1994 Aug;11(3):167-80 PMID: 7831528
  39. Gene expression profiles of primary breast tumors maintained in distant metastases.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 PMID: 14665696
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2006-00-00
Pages
R61
Language
English
Region
England
NLM ID
100927353
PMCID
PMC1779498
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com